Adaptimmune Therapeutics PLC (ADAPY) shareholders
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 1.59B shares
Institutional holders
0
0 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sina Toussi Joint filing with Two Seas Capital LP (8.50%), Two Seas Capital GP LLC (8.50%) | 135,484,206 | 8.50% | 13G (passive) amendment | Jun 30, 2025 |
| Matrix Capital Management Company LP Joint filing with David E. Goel (8.80%) | 135,000,000 | 8.80% | 13G (passive) amendment | Nov 30, 2024 |
| Two Seas Capital LP Joint filing with Two Seas Capital GP LLC (5.80%), Sina Toussi (5.80%) | 89,010,876 | 5.80% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Mar 31, 2026
| Holder | Shares | % of ADAPY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rhumbline Advisers | 3,661 | 0.00% | $72 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0.0% | 0 / 0 | 0 / 9 | 0M | 2M |
| Q4 2025 | 10 | 2M | 0.1% | 1 / 3 | 4 / 46 | 1M | 41M |
| Q3 2025 | 55 | 42M | 2.6% | 14 / 7 | 12 / 24 | 13M | 86M |
| Q2 2025 | 65 | 116M | 7.3% | 11 / 10 | 18 / 11 | 5M | 5M |
| Q1 2025 | 67 | 116M | 7.3% | 8 / 17 | 16 / 19 | 14M | 22M |
| Q4 2024 | 80 | 124M | 7.8% | 14 / 19 | 21 / 14 | 25M | 53M |
| Q3 2024 | 81 | 153M | 9.6% | 18 / 21 | 15 / 12 | 5M | 7M |
| Q2 2024 | 76 | 155M | 9.7% | 7 / 16 | 22 / 11 | 3M | 12M |
| Q1 2024 | 80 | 164M | 10.3% | 16 / 17 | 23 / 15 | 30M | 13M |
| Q4 2023 | 79 | 146M | 9.2% | 14 / 16 | 25 / 14 | 5M | 7M |
| Q3 2023 | 79 | 148M | 9.3% | 7 / 16 | 24 / 17 | 7M | 3M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adrian Rawcliffe | Chief Executive Officer, Director | 44,327 | 0.00% | Feb 20, 2025 |
| Christopher James Hill | Chief Financial Officer | – | – | Oct 8, 2025 |
| Gavin Wood | Chief Financial Officer | 0 | – | Sep 3, 2025 |
| William C. Bertrand JR | Chief Operating Officer | 986,352 | 0.06% | Aug 29, 2025 |
| John Lunger | Chief Patient Supply Officer | 7,510 | 0.00% | Feb 20, 2025 |
| Cintia Piccina | Chief Commercial Officer | 18,421 | 0.00% | Feb 20, 2025 |
| Elliot Norry | Chief Medical Officer | 7,510 | 0.00% | Feb 20, 2025 |
| Joanna Elizabeth Brewer | Chief Scientific Officer | – | – | Feb 20, 2025 |
| Ali Behbahani | Director | 0 | – | Aug 19, 2025 |
| EcoR1 Capital, LLC | 10% owner | 100,371,882 | 6.31% | Jul 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gavin Wood Chief Financial Officer | Sep 2, 2025 | Sale | −96,000 | $0.01 | $960 | 0 |
| William C. Bertrand JR Chief Operating Officer | Aug 28, 2025 | Sale | −207,000 | $0.01 | $2.07K | 986,352 |
| Ali Behbahani Director | Aug 18, 2025 | Sale | −14,671,794 | $0.01 | $146.72K | 0 |
| Ali Behbahani Director | Aug 15, 2025 | Sale | −4,828,206 | $0.01 | $48.28K | 14,671,794 |
| EcoR1 Capital, LLC 10% owner | Jul 30, 2025 | Sale | −27,433,338 | $0.10 | $2.74M | 100,371,882 |
| EcoR1 Capital, LLC 10% owner | Jul 29, 2025 | Sale | −2,687,460 | $0.10 | $268.75K | 127,805,220 |
| EcoR1 Capital, LLC 10% owner | Jul 28, 2025 | Sale | −33,931,740 | $0.11 | $3.73M | 130,492,680 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2025 | Sale | −5,584 | $0.58 | $3.24K | 7,510 |
| Elliot Norry Chief Medical Officer | Jan 17, 2025 | Sale | −5,584 | $0.58 | $3.24K | 7,510 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 17, 2025 | Sale | −30,601 | $0.58 | $17.75K | 44,327 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2025 | Sale | −5,584 | $0.58 | $3.24K | 7,510 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 15, 2025 | Sale | −29,096 | $0.57 | $16.58K | 41,582 |
| William C. Bertrand JR Chief Operating Officer | Jan 15, 2025 | Sale | −9,803 | $0.57 | $5.59K | 13,756 |
| Cintia Piccina Chief Commercial Officer | Jan 15, 2025 | Sale | −12,991 | $0.57 | $7.40K | 18,421 |
| Elliot Norry Chief Medical Officer | Jan 15, 2025 | Sale | −9,803 | $0.57 | $5.59K | 13,756 |
| John Lunger Chief Patient Supply Officer | Jan 15, 2025 | Sale | −9,803 | $0.57 | $5.59K | 13,756 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 13, 2025 | Sale | −17,934 | $0.59 | $10.58K | 25,711 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 13, 2025 | Sale | −12,539 | $0.59 | $7.40K | 17,801 |
| William C. Bertrand JR Chief Operating Officer | Jan 13, 2025 | Sale | −4,268 | $0.59 | $2.52K | 5,845 |
| William C. Bertrand JR Chief Operating Officer | Jan 13, 2025 | Sale | −5,471 | $0.59 | $3.23K | 7,623 |
| Elliot Norry Chief Medical Officer | Jan 13, 2025 | Sale | −8,124 | $0.59 | $4.79K | 11,516 |
| Elliot Norry Chief Medical Officer | Jan 13, 2025 | Sale | −4,268 | $0.59 | $2.52K | 5,845 |
| John Lunger Chief Patient Supply Officer | Jan 13, 2025 | Sale | −4,268 | $0.59 | $2.52K | 5,845 |
| John Lunger Chief Patient Supply Officer | Jan 13, 2025 | Sale | −5,471 | $0.59 | $3.23K | 7,623 |
| Cintia Piccina Chief Commercial Officer | Jun 18, 2024 | Sale | −24,531 | $0.93 | $22.81K | 38,293 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2024 | Sale | −5,309 | $0.67 | $3.56K | 7,785 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2024 | Sale | −13,599 | $0.67 | $9.11K | 20,201 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2024 | Sale | −12,805 | $0.67 | $8.58K | 19,015 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2024 | Sale | −5,309 | $0.67 | $3.56K | 7,785 |
| Elliot Norry Chief Medical Officer | Jan 17, 2024 | Sale | −12,967 | $0.67 | $8.69K | 19,257 |
| Elliot Norry Chief Medical Officer | Jan 17, 2024 | Sale | −5,309 | $0.67 | $3.56K | 7,785 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 17, 2024 | Sale | −30,080 | $0.67 | $20.15K | 44,848 |
| William C. Bertrand JR Chief Operating Officer | Jan 16, 2024 | Sale | −4,681 | $0.79 | $3.70K | 7,023 |
| John Lunger Chief Patient Supply Officer | Jan 16, 2024 | Sale | −4,681 | $0.79 | $3.70K | 7,023 |
| Elliot Norry Chief Medical Officer | Jan 16, 2024 | Sale | −2,287 | $0.79 | $1.81K | 3,363 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 16, 2024 | Sale | −9,304 | $0.79 | $7.35K | 14,104 |
| John Lunger Chief Patient Supply Officer | Jan 12, 2024 | Sale | −5,220 | $0.85 | $4.44K | 7,874 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 12, 2024 | Sale | −17,257 | $0.85 | $14.67K | 26,388 |
| Elliot Norry Chief Medical Officer | Jan 12, 2024 | Sale | −7,799 | $0.85 | $6.63K | 11,841 |
| William C. Bertrand JR Chief Operating Officer | Jan 12, 2024 | Sale | −5,220 | $0.85 | $4.44K | 7,874 |
| John Lunger Chief Patient Supply Officer | Jan 11, 2024 | Sale | −4,009 | $0.84 | $3.37K | 6,104 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 11, 2024 | Sale | −11,945 | $0.84 | $10.03K | 18,395 |
| Elliot Norry Chief Medical Officer | Jan 11, 2024 | Sale | −4,009 | $0.84 | $3.37K | 6,104 |
| William C. Bertrand JR Chief Operating Officer | Jan 11, 2024 | Sale | −4,009 | $0.84 | $3.37K | 6,104 |
| Adrian Rawcliffe Chief Executive Officer, Director | Sep 1, 2023 | Sale | −2,403 | $0.78 | $1.87K | 3,449 |
| John Lunger Chief Patient Supply Officer | Aug 1, 2023 | Sale | −3,096 | $0.91 | $2.82K | 4,718 |
| Garry E. Menzel Director | Jul 10, 2023 | Sale | −47,702 | $0.91 | $43.41K | 75,056 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jun 27, 2023 | Sale | −2,333 | $0.92 | $2.15K | 3,519 |
| Garry E. Menzel Director | Jun 1, 2023 | Award | +200,646 | – | – | 200,646 |
| Garry E. Menzel Director | Jun 1, 2023 | Award | +200,647 | – | – | 200,647 |
| Garry E. Menzel Director | Jun 1, 2023 | Award | +209,931 | – | – | 209,931 |
| Cintia Piccina Chief Commercial Officer | Jan 31, 2023 | Sale | −11,890 | $1.87 | $22.23K | 19,535 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2023 | Sale | −4,440 | $1.86 | $8.26K | 7,264 |
| Elliot Norry Chief Medical Officer | Jan 17, 2023 | Sale | −2,159 | $1.86 | $4.02K | 3,491 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 17, 2023 | Sale | −10,057 | $1.86 | $18.71K | 13,351 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2023 | Sale | −4,440 | $1.86 | $8.26K | 7,264 |
| William C. Bertrand JR Chief Operating Officer | Jan 12, 2023 | Sale | −4,973 | $1.71 | $8.50K | 8,121 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 12, 2023 | Sale | −18,763 | $1.71 | $32.08K | 24,882 |
| Elliot Norry Chief Medical Officer | Jan 12, 2023 | Sale | −7,449 | $1.71 | $12.74K | 12,191 |
| John Lunger Chief Patient Supply Officer | Jan 12, 2023 | Sale | −4,973 | $1.71 | $8.50K | 8,121 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
1M shares short
Days to cover
3.1
At 0M shares a day
Change since last report
+0.0%
From 1M shares
Short volume, 0 days
–
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Adaptimmune Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,000 shares on Oct 6, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Gavin Wood Chief Financial Officer | Sep 2, 2025 | 16,000 | $942 | Sep 2, 2025 | Open market purchase |
| William C. Bertrand JR Chief Operating Officer | Aug 29, 2025 | 34,500 | $2.07K | Aug 28, 2025 | Open market purchase |
| New Enterprise Associates, 14 LP Affiliate | Aug 15, 2025 | 13,829,778 | $981.91K | Aug 15, 2025 | Private Placement |
| New Enterprise Associates, 16 LP Affiliate | Aug 15, 2025 | 3,250,000 | $230.75K | Aug 15, 2025 | Private Placement |
| Elliot Norry Chief Medical Officer | Jan 17, 2025 | 5,584 | $3.24K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| Adrian Rawcliffe Chief Executive Officer | Jan 17, 2025 | 30,601 | $17.77K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| John Lunger Chief Patient Supply Officer | Jan 17, 2025 | 5,584 | $3.24K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2025 | 5,584 | $3.24K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| Elliot Norry Chief Medical Officer | Jan 15, 2025 | 22,195 | $12.92K | Jan 13, 2025 | Sell to cover exercise (cashless) |
| Adrian Rawcliffe Chief Executive Officer | Jan 15, 2025 | 59,569 | $34.64K | Jan 13, 2025 | Sell to cover exercise (cashless) |
| Cintia Piccina Chief Commercial Officer | Jan 15, 2025 | 12,991 | $7.47K | Jan 15, 2025 | Sell to cover exercise (cashless) |
| William C. Bertrand JR Chief Operating Officer | Jan 15, 2025 | 19,542 | $11.36K | Jan 13, 2025 | Sell to cover exercise (cashless) |
| John Lunger Chief Patient Supply Officer | Jan 15, 2025 | 19,542 | $11.36K | Jan 13, 2025 | Sell to cover exercise (cashless) |
See a number that looks wrong?